Histogen, Inc.

118 articles with Histogen, Inc.

• Histogen to Present at the H.C. Wainwright Global Investment Conference

  5/17/2022

  Histogen Inc. announced that Steven J. Mento, Ph.D., Histogen’s Executive Chairman and Interim President and Chief Executive Officer, will present at the H.C. Wainwright Global Investment Conference.

• Histogen Reports First Quarter 2022 Financial Results and Provides Business Update

  5/12/2022

  Histogen Inc. reported financial results for the first quarter ended March 31, 2022 and provided an update on its clinical pipeline and other corporate developments.

• Histogen to Report First Quarter 2022 Financial Results and Provide Business Update

  4/28/2022

  Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing both restorative therapeutics and pan-caspase and caspase selective inhibitors focused on treatments for infectious and inflammatory diseases, today announced that Histogen’s financial results for the first quarter ended March 31, 2022 will be released after the close of market on Thursday, May 12, 2022.

• Histogen Announces Closing of $4.75 Million Private Placement

  3/25/2022

  Histogen Inc. announced the closing of its previously announced private placement for the issuance and sale of 2,500 shares of Series A redeemable convertible preferred stock and 2,500 shares of Series B redeemable convertible preferred stock.

• Histogen Announces $4.75 Million Private Placement

  3/23/2022

  Histogen Inc. announced that it has entered into a securities purchase agreement with certain institutional investors to purchase 2,500 shares of Series A redeemable convertible preferred stock and 2,500 shares of Series B redeemable convertible preferred stock.

• Histogen Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Business UpdatePhase 1/2 Study of HST 003 for Cartilage Regeneration in the Knee Ongoing with Top-Line Data Anticipated in the First Half of 2023

  3/10/2022

  Histogen Inc. reported financial results for the fourth quarter and year ended December 31, 2021 and provided an update on its clinical pipeline and other corporate developments.

• Histogen to Report Fourth Quarter and Year-End 2021 Financial Results and Provide Business Update

  3/3/2022

  Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the body’s natural process to repair and maintain healthy biological function, today announced that Histogen’s financial results for the fourth quarter and year ended December 31, 2021 will be released after the close of market on Thursday, March 10, 2022.

• Histogen Announces Closing of $3.5 Million Private Placement

  12/21/2021

  Histogen Inc. announced the closing of its previously announced private placement for the issuance and sale of 8,235,297 shares of common stock and warrants to purchase up to an aggregate of 8,235,297 shares of common stock, at a purchase price of $0.425 per share of common stock and associated warrant.

• Histogen Announces $3.5 Million Private Placement

  12/16/2021

  Histogen Inc. (NASDAQ: HSTO), announced today that it has entered into securities purchase agreements with certain institutional and accredited investors to issue, in a private placement, 8,235,297 shares of common stock (or pre-funded warrants in lieu thereof) and warrants to purchase up to an aggregate of 8,235,297 shares of common stock.

• Histogen Reports Third Quarter 2021 Earnings and Provides Business Update

  11/10/2021

  Histogen Inc. (NASDAQ: HSTO), today reported financial results for the third quarter ended September 30, 2021 and provided an update on its clinical pipeline and other corporate developments.

• Histogen Announces CEO Transition

  11/8/2021

  Histogen Inc., a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the body’s natural process to repair and maintain healthy biological function, announced that that Steven J. Mento, Ph.D., a current member of the Histogen Board of Directors, has been appointed Executive Chairman and Interim President and Chief Executive Officer effective immediately.

• 

  Clinical Catch-Up: November 1-5

  11/8/2021

  The first week of November was marked by numerous clinical trial announcements. Here’s a look.

• Histogen and Amerimmune Announce the Presentation of Emricasan Data in COVID-19 at the American College of Allergy, Asthma, and Immunology Conference

  11/2/2021

  Histogen Inc. today announced that Amerimmune’s CEO, Oral Alpan, MD, will present updated findings from the emricasan Phase 1 study in mild symptomatic COVID-19 patients at the American College of Allergy, Asthma, and Immunology Conference in New Orleans on November 6, 2021.

• Histogen to Report Third Quarter 2021 Financial Results on November 10, 2021

  10/27/2021

  Histogen Inc., a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the body’s natural process to repair and maintain healthy biological function, announced that Histogen’s financial results for the third quarter will be released after the close of market on Wednesday, November 10, 2021.

• Histogen to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

  8/31/2021

  Histogen Inc. (NASDAQ: HSTO), today announced that Richard W. Pascoe, President and Chief Executive Officer of Histogen, will present at the H.C. Wainwright 23rd Annual Global Investment Conference.

• 

  Clinical Catch-Up: August 16-20

  8/23/2021

  It was another busy week in clinical trial news. Here’s a look.

• Histogen and Amerimmune Announce Additional Findings from its Phase 1 Study of Emricasan in Mild Symptomatic COVID-19 Patients

  8/16/2021

  Histogen Inc. and its partner Amerimmune, LLC today announced additional findings from its Phase 1 study of emricasan in mild symptomatic COVID-19 patients to assess safety, tolerability, and preliminary efficacy.

• Histogen Reports Second Quarter 2021 Earnings and Provides Business Update

  8/11/2021

  Histogen Inc. (NASDAQ: HSTO), a clinical-stage company focused on developing potential first-in-class restorative therapeutics that ignite the body’s natural process to repair and maintain healthy biological function, today reported financial results for the second quarter ended June 30, 2021 and provided an update on its clinical pipeline and other corporate developments.

• Histogen to Present at the Canaccord Genuity 41st Annual Growth Conference

  7/29/2021

  Histogen Inc., a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the body’s natural process to repair and maintain healthy biological function, announced that Richard W. Pascoe, President and Chief Executive Officer of Histogen, will present at the Canaccord Genuity 41st Annual Growth Conference.

• Histogen to Report Second Quarter 2021 Financial Results on August 11, 2021

  7/28/2021

  Histogen Inc., a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the body’s natural process to repair and maintain healthy biological function, announced that Histogen’s financial results for the second quarter will be released after the close of market on Wednesday, August 11, 2021.